

Idiopathic Pulmonary Fibrosis (IPF)

Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03208933 ML39355

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03208933 ML39355
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 40 Years & <= 80 Years

Healthy Volunteers
No
